18 May 2021
Clinical event reductions in high-risk hypertension patients treated with renal denervation
Sponsored by Medtronic
Speaker:
R. Schmieder
Summary
Watch this session presented by Roland Schmieder in order to learn about the long-term safety and efficacy of renal denervation in high-risk subgroups from the largest renal denervation data set of real-world patients, to understand how clinical event rates could be reduced following renal denervation as compared to a modelled control group, and to learn about potential clinical and economic implications of renal denervation treatment of hypertension over longer-term horizons.
View a related EuroPCR 2021 Session on "Redefining hypertension management with renal denervation".
Learning Objectives
- To learn about the long-term safety and efficacy of renal denervation in high-risk subgroups from the largest renal denervation data set of real-world patients
- To understand how clinical event rates could be reduced following renal denervation as compared to a modelled control group
- To learn about potential clinical and economic implications of renal denervation treatment of hypertension over longer-term horizons